Aliases & Classifications for Blepharitis

MalaCards integrated aliases for Blepharitis:

Name: Blepharitis 12 77 38 30 56 6 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9423
KEGG 38 H01644
MeSH 45 D001762
NCIt 51 C112183
SNOMED-CT 69 41446000

Summaries for Blepharitis

Disease Ontology : 12 An eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow.

MalaCards based summary : Blepharitis is related to keratosis follicularis spinulosa decalvans, x-linked and blepharoconjunctivitis, and has symptoms including erythema of the eyelids An important gene associated with Blepharitis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Immune response Role of DAP12 receptors in NK cells and Development IGF-1 receptor signaling. The drugs Acitretin and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes, and related phenotypes are cellular and immune system

Wikipedia : 77 Blepharitis (/blɛfəˈraɪtɪs/ BLEF-ər-EYE-tis) is one of the most common ocular conditions characterized... more...

Related Diseases for Blepharitis

Diseases related to Blepharitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 keratosis follicularis spinulosa decalvans, x-linked 32.3 MBTPS2 SAT1
2 blepharoconjunctivitis 31.9 CCL11 IL4 SHE
3 ectropion 30.4 MBTPS2 SAT1
4 keratoconjunctivitis 29.7 CCL11 IL4
5 papillary conjunctivitis 29.7 CCL11 IL4
6 giant papillary conjunctivitis 29.6 CCL11 IL4
7 ulcerative blepharitis 12.3
8 squamous blepharitis 12.3
9 focal facial dermal dysplasia 3, setleis type 11.2
10 ichthyosis, congenital, autosomal recessive 11 11.1
11 hordeolum externum 11.1
12 eyelid disease 11.1
13 meibomian cyst 11.1
14 conjunctivitis 10.5
15 keratosis follicularis spinulosa decalvans 10.3 MBTPS2 SAT1
16 corneal degeneration 10.3 MBTPS2 SAT1
17 herpes simplex 10.3
18 lupus erythematosus 10.3
19 rosacea 10.3
20 venezuelan equine encephalitis 10.2 SAT1 STAT1
21 discoid lupus erythematosus 10.2
22 chronic meningitis 10.2 CCL11 MMP9
23 central nervous system tuberculosis 10.2 MMP9 STAT1
24 strongyloidiasis 10.1 CCL11 SHE
25 dermatitis 10.1
26 crohn's colitis 10.0
27 phlyctenulosis 10.0
28 scleritis 10.0 IL4 MMP9
29 chromoblastomycosis 10.0 IL4 MMP9
30 hair disease 9.9 MBTPS2 SAT1
31 chronic conjunctivitis 9.9 CCL11 IL4
32 eosinophilic gastritis 9.9 CCL11 IL4
33 autoimmune disease 9.9
34 systemic lupus erythematosus 9.9
35 melkersson-rosenthal syndrome 9.9
36 rheumatoid arthritis 9.9
37 trichomegaly 9.9
38 lipoid proteinosis of urbach and wiethe 9.9
39 dermatitis, atopic 9.9
40 basal cell carcinoma 1 9.9
41 anxiety 9.9
42 riboflavin deficiency 9.9
43 alopecia 9.9
44 arthritis 9.9
45 cataract 9.9
46 crohn's disease 9.9
47 cutaneous leishmaniasis 9.9
48 keratoconus 9.9
49 neutropenia 9.9
50 colitis 9.9

Comorbidity relations with Blepharitis via Phenotypic Disease Network (PDN):


Acute Cystitis Conjunctivitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Parkinson Disease, Late-Onset Schizophreniform Disorder

Graphical network of the top 20 diseases related to Blepharitis:



Diseases related to Blepharitis

Symptoms & Phenotypes for Blepharitis

UMLS symptoms related to Blepharitis:


erythema of the eyelids

MGI Mouse Phenotypes related to Blepharitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.7 IL4 MMP9 NGLY1 NIPBL PLA2G6 SAT1
2 immune system MP:0005387 9.5 CCL11 IL4 MMP9 NIPBL PLA2G6 STAT1
3 skeleton MP:0005390 9.1 IL4 MMP9 NIPBL PLA2G6 STAT1 WIPF1

Drugs & Therapeutics for Blepharitis

Drugs for Blepharitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
3
Besifloxacin Approved Phase 4 141388-76-3
4
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
6
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
7
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 5496 36294
8
Minocycline Approved, Investigational Phase 4,Not Applicable 10118-90-8 5281021
9
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
10
Glycerol Approved, Investigational Phase 4 56-81-5 753
11
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
12
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
15
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
16
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
17
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
18
Chloramphenicol succinate Approved Phase 4 3544-94-3
19
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
20 Keratolytic Agents Phase 4
21 Dermatologic Agents Phase 4,Not Applicable
22 Ophthalmic Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Viscosupplements Phase 4,Not Applicable
25 Adjuvants, Immunologic Phase 4,Not Applicable
26 Protective Agents Phase 4,Not Applicable
27 Immunologic Factors Phase 4,Phase 2,Not Applicable
28 Erythromycin Estolate Phase 4
29 Erythromycin Ethylsuccinate Phase 4
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Erythromycin stearate Phase 4
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Lubricant Eye Drops Phase 4,Phase 1,Phase 2
36 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
37 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Antimalarials Phase 4,Phase 2,Not Applicable
40 Carboxymethylcellulose Sodium Phase 4
41 Cathartics Phase 4
42 Laxatives Phase 4
43 Analgesics Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Antirheumatic Agents Phase 4,Phase 1,Phase 2,Not Applicable
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
50 Hormones Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
2 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis Completed NCT01478256 Phase 4 Erythromycin;Besifloxocin
3 Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis Completed NCT01357538 Phase 4 Posiformin 2 %, bibrocathol;Placebo Comparator
4 Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis Completed NCT00629941 Phase 4 AzaSite®
5 Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis Completed NCT00656539 Phase 4 AzaSite®
6 Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis Completed NCT00629980 Phase 4 AzaSite®
7 Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis Completed NCT00629590 Phase 4 AzaSite®
8 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
9 Lipids of the Human Tear Film and Their Effect on Tear Stability Completed NCT00803452 Phase 4 doxycycline;azithromycin
10 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
11 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
12 Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed NCT00447577 Phase 4 Loteprednol etabonate and tobramycin ophthalmic suspension;Tobramycin and dexamethasone ophthalmic suspension
13 The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis Enrolling by invitation NCT03105505 Phase 4 Permethrin 5%;Synthomycine 5%;Fusidic Acid 1% M/R Eye Drops
14 Manuka Eye Droops for Treatment of Allergy Not yet recruiting NCT03862053 Phase 4 Manuka honey
15 A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis Completed NCT01102244 Phase 3 Tobradex ST;Azasite
16 Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1% Completed NCT02236403 Phase 3 Ivermectin 0.1% Metronidazole 1%
17 Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis Completed NCT01408082 Phase 3 ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined);Azasite;Dexamethasone
18 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
19 Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Completed NCT00796926 Phase 3 Systane Ultra eyedrops;Refresh eye drops
20 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3 Loteprednol and tobramycin;Tobramycin and dexamethasone
21 Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops Completed NCT01087671 Phase 3 tafluprost
22 Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects Recruiting NCT01543490 Phase 3 ISV-305
23 Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
24 Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Unknown status NCT02300818 Phase 1, Phase 2 Seawater eyedrops
25 Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 Unknown status NCT02656394 Phase 2 GL101;Placebo
26 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis Completed NCT01783860 Phase 2 Azithromycin;Doxycycline
27 Tea Tree Oil in the Treatment of Chronic Blepharitis Completed NCT01073150 Phase 2 Tea Tree Oil
28 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Completed NCT01089608 Phase 2 Azithromycin;Povidone
29 Topical IL-1-Ra for Treatment of Posterior Blepharitis Completed NCT00681109 Phase 1, Phase 2 2.5% IL-1Ra;Placebo;5% IL-1Ra
30 Treatment of Patients With Blepharitis and Facial Rosacea Completed NCT00560703 Phase 2 COL-101 (doxycycline, USP) capsules;placebo
31 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Completed NCT00892970 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
32 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Completed NCT00894530 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
33 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Completed NCT02218489 Phase 2 KPI-121;Vehicle
34 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
35 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting NCT01740297 Phase 1, Phase 2 Talimogene laherparepvec;Ipilimumab
36 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636) Terminated NCT01269658 Phase 2 Azithromycin ophthalmic solution, 1%;Vehicle
37 A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641) Terminated NCT01220258 Phase 2 Azithromycin ophthalmic solution, 1%
38 A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates Terminated NCT00579020 Phase 2 Moxifloxacin/dexamethasone phosphate ophthalmic solution;Moxifloxacin ophthalmic solution 0.5%;Dexamethasone phosphate solution, 0.1%
39 Study to Determine the Effect of Azasite on Corneal Surface Irregularity Withdrawn NCT01797107 Phase 2 Azasite
40 Demodex Blepharitis Treatment Study Completed NCT01647217 Phase 1 Terpinen-4-ol
41 Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora Unknown status NCT02455895 Not Applicable
42 Ocular Comfort and Inflammation in Lid Hygiene Therapy Unknown status NCT02938078 Not Applicable
43 Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma Unknown status NCT01284439 Not Applicable hydroxypropylmethylcellulose;sodium hyaluronate
44 Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens Unknown status NCT02812316 Not Applicable
45 Blephacura Versus Baby Shampoo to Treat Blepharitis Completed NCT01115192 Not Applicable
46 To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis Completed NCT03301844 Not Applicable
47 Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis Completed NCT02952079 Not Applicable
48 Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery Completed NCT01808560 Not Applicable
49 Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points Completed NCT00345241 Not Applicable Systane Ocular Drops (OTC);Placebo - Saline Drops
50 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Completed NCT00344721 Not Applicable

Search NIH Clinical Center for Blepharitis

Cochrane evidence based reviews: blepharitis

Genetic Tests for Blepharitis

Genetic tests related to Blepharitis:

# Genetic test Affiliating Genes
1 Blepharitis 30

Anatomical Context for Blepharitis

MalaCards organs/tissues related to Blepharitis:

42
Eye, Skin, Testes

Publications for Blepharitis

Articles related to Blepharitis:

(show top 50) (show all 306)
# Title Authors Year
1
MEN 2B masquerading as chronic blepharitis and euryblepharon. ( 30688132 )
2019
2
Long Term Side effects Including Blepharitis Leading to Discontinuation of Ripasudil. ( 30720574 )
2019
3
Blepharitis in dogs: a clinical evaluation in 102 dogs. ( 30828906 )
2019
4
Is it always blepharitis? Urbach-Wiethe syndrome (lipoid proteinosis). ( 30916217 )
2019
5
Better detection of <i>Demodex</i> mites by LAPffler's alkaline methylene blue staining in patients with blepharitis. ( 29713140 )
2018
6
Satisfaction and convenience of using terpenoid-impregnated eyelid wipes and teaching method in people without blepharitis. ( 29379270 )
2018
7
The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. ( 29074306 )
2018
8
Eyelid tinea with blepharitis due to Microsporum canis. ( 29859733 )
2018
9
Comparison of the Clinical Efficacy of Topical and Systemic Azithromycin Treatment for Posterior Blepharitis. ( 29493395 )
2018
10
Development and evaluation of a measure of patient-reported symptoms of Blepharitis. ( 29325546 )
2018
11
Randomized double-masked trial of eyelid cleansing treatments for blepharitis. ( 29128682 )
2018
12
The use of tea tree oil in treating blepharitis and meibomian gland dysfunction. ( 29563688 )
2018
13
The impact of age, sex, blepharitis, rosacea and rheumatoid arthritis on <i>Demodex</i> mite infection. ( 29593809 )
2018
14
Blepharitis caused by deep trichophytosis - tinea ciliaris. ( 29927550 )
2018
15
Chronic blepharitis. ( 29947143 )
2018
16
Tiefe Trichophytie unter dem Bild einer Blepharitis - Tinea ciliaris. ( 29989360 )
2018
17
Evaluation of the Efficacy of Tea Tree Oil On the Density of Demodex Mites (Acari: Demodicidae) and Ocular Symptoms In Patients With Demodectic Blepharitis. ( 30016200 )
2018
18
Relationship between blepharitis and components of the metabolic syndrome. ( 30031612 )
2018
19
Investigation of Demodex Parasite Existence in Treatment-Resistant Chronic Blepharitis Cases. ( 30070644 )
2018
20
Quantitative Analysis of the Bacteria in Blepharitis With Demodex Infestation. ( 30108572 )
2018
21
Safety and efficacy of 4-terpineol against microorganisms associated with blepharitis and common ocular diseases. ( 30123842 )
2018
22
Prevalence and Load of Demodex folliculorum and Demodex brevis (Acari: Demodicidae) in Patients With Chronic Blepharitis in the Province of Erzincan, Turkey. ( 30137440 )
2018
23
Demodex blepharitis: clinical perspectives. ( 30214343 )
2018
24
Phthiriasis palpebrarum presenting as anterior blepharitis. ( 30232978 )
2018
25
Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study. ( 30255395 )
2018
26
Blepharitis Preferred Practice Pattern®. ( 30366800 )
2018
27
Association of Blepharitis and Ectropion With Tumor Necrosis Factor α Inhibitor Treatment in Crohn Disease. ( 30419086 )
2018
28
Severe chronic blepharitis. Torpid evolution of several years. ( 30447950 )
2018
29
Healthcare delivery in meibomian gland dysfunction and blepharitis. ( 30458245 )
2018
30
Blepharitis as an early sign of metabolic syndrome: a nationwide population-based study. ( 29146760 )
2017
31
High prevalence of Demodex spp. infestation among patients with posterior blepharitis: correlation with age and cylindrical dandruff. ( 28552438 )
2017
32
Blepharitis ( 29083763 )
2017
33
Chronic blepharitis like picture in patients with Discoid lupus erythematosis - Case series. ( 29634708 )
2017
34
Meibography for eyes with posterior blepharitis. ( 28860908 )
2017
35
Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099. ( 28605219 )
2017
36
Preclinical development of MGO Manuka Honey microemulsion for blepharitis management. ( 29354709 )
2017
37
Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis. ( 29354710 )
2017
38
Tacrolimus Ointment for Refractory Posterior Blepharitis. ( 28922018 )
2017
39
The association of keratoconus with blepharitis. ( 29232760 )
2017
40
Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study. ( 28183148 )
2017
41
Unilateral Blepharitis With Fine Follicular Scaling. ( 28920471 )
2017
42
Demodex Blepharitis Treated with a Novel Dilute Povidone-Iodine and DMSO System: A Case Report. ( 28643231 )
2017
43
Blepharitis With Facial Numbness and Ocular Pain. ( 28880989 )
2017
44
Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. ( 26788833 )
2016
45
Recurrent Fungal Keratitis and Blepharitis Caused by Aspergillus flavus. ( 27621301 )
2016
46
Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis. ( 27349766 )
2016
47
DEBS - a unification theory for dry eye and blepharitis. ( 28003734 )
2016
48
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin-0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis. ( 27570444 )
2016
49
Oral azithromycin and blepharitis: symptoms and signs improve, so where are the publications? ( 27356302 )
2016
50
Meibomian gland dysfunction: azithromycin and objective improvement in outcomes in posterior blepharitis. ( 27314917 )
2016

Variations for Blepharitis

ClinVar genetic disease variations for Blepharitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh37 Chromosome 2, 191859910: 191859910
2 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh38 Chromosome 2, 190995184: 190995184

Expression for Blepharitis

Search GEO for disease gene expression data for Blepharitis.

Pathways for Blepharitis

GO Terms for Blepharitis

Biological processes related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of release of cytochrome c from mitochondria GO:0090200 8.96 MMP9 PLA2G6
2 cytokine-mediated signaling pathway GO:0019221 8.92 CCL11 IL4 MMP9 STAT1

Sources for Blepharitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....